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Overview
The ABCs of psychosis 
• Do you ever think that people are out to get you?
• Do you hear voices when no one is there or see things that 
shouldn’t be there?
• Do you have unusual abilities or powers?
• Do you sometimes believe things on TV or online are 
personally directed at you?
These are just a few of the questions practitioners ask to 
help them understand the distressing experiences of a young 
person with psychosis.
The hallmark symptoms
Adolescents with psychosis have difficulty with thinking, behaving and 
communicating — and with understanding reality. These challenges can 
seriously impair their development and functioning. Table 1 describes the 
hallmark symptoms of psychosis.
Psychotic symptoms are often classified as either “positive” or “negative.” 
Positive symptoms include delusions and hallucinations. In contrast, negative 
symptoms are characterized by a loss or reduction in typical functioning1 and 
include flat affect, limited speech and diminished energy.2 Negative 
symptoms are thought to have a stronger effect on cognitive and other areas  
of functioning than positive symptoms.3
  Psychotic symptoms are essentially 
signals that the brain is not functioning 
properly.
Table 1:  Psychotic symptoms
Symptom Definition1  Example
Delusions 
Hallucinations
   
Disorganized Behaviours 
Strongly held false beliefs involving a 
misinterpretation of sensory information or 
experiences often based on a given theme.
Perceptions occurring in any of the five senses 
without external stimuli. Auditory hallucinations 
are the most frequent. 
Behaviours preventing effective functioning, 
including difficulties engaging in goal-directed 
actions, incoherent speech and agitation.
Sanjit believes the creators of a new and extremely 
popular video game have included hidden 
messages in the game that only he can decipher.
Jenny alone hears a voice warning that her biology 
teacher is trying to harm her.
Quon abruptly starts rambling on about food 
safety while his mother is preparing to leave for 
work. This, and his poor hygiene, cause Quon’s 
mother to be increasingly worried about his well-
being. 
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The differing reasons for psychosis
Psychotic symptoms are essentially signals 
that the brain is not functioning properly. 
Such symptoms can occur in many different 
conditions, including schizophrenia, 
schizophreniform disorder, schizoaffective 
disorder, delusional disorder, brief psychotic 
disorder, bipolar disorder and major depression 
with psychotic features. Psychosis can also be 
caused by substance use (including intoxication 
or withdrawal from alcohol, street drugs or 
prescription medications) and medical conditions 
(such as infection, epilepsy, head injury, cancer 
or autoimmune disorders).1 Collectively, these 
conditions are referred to as psychotic disorders. 
Because most of the high-quality research on 
psychotic disorders focuses on schizophrenia, here 
we mainly focus on this condition. (Additional 
information on depression and bipolar disorder 
can be found in previous issues of the Quarterly.) 
More than a numbers game
Although limited information exists on the number of children affected 
by psychosis across all diagnostic categories, high-quality epidemiological 
data on schizophrenia have been collected. These data show that while 
schizophrenia does affect young people, it rarely begins in childhood. 
Among children age 9 to 13, for example, the estimated prevalence is only 
0.1%, or 1 in 1,000.4 This suggests that only 300 children in this age range 
in British Columbia (or 2,100 in Canada) would meet diagnostic criteria for 
schizophrenia.5 However, the disorder becomes increasingly prevalent in later 
adolescence, eventually reaching an estimated prevalence of 1%, or 1 in 100, 
for the population as a whole.1 Furthermore, among individuals who are 
eventually diagnosed with schizophrenia, nearly one-third will experience 
their first psychotic episode by age 19.6
Gender differences in incidence and prevalence of schizophrenia are quite 
pronounced. Males have a 30% to 40% higher lifetime risk of developing 
the condition than females.7 As well, the peak age of onset for schizophrenia 
among males is 18 to 23 years, compared with 25 to 35 years for females.8
Overview continued
  Up to 80% of individuals will 
experience a remission of psychotic 
symptoms within their first year of 
treatment with antipsychotic medication.
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A typical course
Schizophrenia usually includes periods of illness mixed with periods of 
remission.9 It typically begins with a “prodromal” stage during which a 
youth’s functioning noticeably declines.2 Characteristic symptoms include 
social withdrawal, poor self-care, suspiciousness, apathy, sleep disturbances 
and mood changes (including irritability and low mood).3 This prodromal 
stage can last from weeks to years.10 It is usually followed by an acute phase, 
marked by delusions and hallucinations, typically lasting from one to six 
months.10 Most adolescents then experience several months of significant 
negative symptoms without acute psychotic symptoms.10 The cycle often 
then begins again with similar declines in functioning followed by the re-
emergence of positive symptoms, particularly if adolescents do not receive 
early diagnosis and treatment.9
Although most adolescents with schizophrenia continue to experience 
the disorder as adults, outcomes vary a great deal.11 A better short-term 
course is associated with better long-term outcomes.12 As well, up to 80% of 
individuals will experience a remission of psychotic symptoms within their 
first year of treatment with antipsychotic medication.13
What causes schizophrenia?
In some cases, the cause of psychosis can be clearly identified and treated, for 
example, when it is due to substance use or a medical condition. However, 
the cause of psychotic disorders such as schizophrenia is considerably more 
complicated, involving genetic as well as environmental factors.
Evidence of the importance of genetics comes, in part, from studies 
finding that adopted monozygotic twins (who share most genetic material 
while being raised in different environments) are four times more likely to 
both be diagnosed with schizophrenia than adopted dizygotic twins (who 
share somewhat less genetic material).8 Although the genes involved have yet 
to be conclusively identified, current research suggests that the development 
of schizophrenia is likely due to complex genetic interactions (including 
gene-environment interactions), rather than to any single gene.8 Nonetheless, 
it is important to recognize that most children and youth with genetic 
vulnerability for schizophrenia will not develop the disorder. For example, 
a study of women with schizophrenia found that only 6.7% of their children 
developed the disorder.14
Schizophrenia is also increasingly being recognized as a neuro-
developmental disorder, in part because many individuals with schizophrenia 
have a history of abnormal fetal development and birth complications.7 As 
well, disruptions in brain development are often found among individuals 
who eventually develop schizophrenia. Expressions of these challenges can 
Overview continued
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include delayed achievement of developmental milestones, reduced cognitive 
functioning, limited social competence and challenges in motor skills.7
Although environmental factors do not cause schizophrenia per se, 
they can play a role in its development, likely through influencing gene 
expression. For example, some studies have found that individuals born in 
urban areas have 2 to 4 times the risk of developing schizophrenia compared 
to those born in rural areas.7 These differences exist despite the incidence of 
schizophrenia being very similar across regions and cultures.15 As well, the 
risk of schizophrenia is 2 to 25 times higher among individuals who have 
used marijuana.7 Because of study design limitations, it cannot be concluded 
that marijuana use caused schizophrenia. Rather, it is possible that marijuana 
use resulted in schizophrenia presenting earlier in young people who 
eventually would have developed the disorder anyway. Other variables, such 
as parenting practices, are now clearly known to not cause schizophrenia.16
The importance of accurate diagnosis 
Identifying children and adolescents with psychosis is a fundamental 
precursor to providing appropriate treatment. Unfortunately, many barriers 
can hamper a timely and accurate diagnosis. For example, there is often a 
significant delay (averaging nine months)17 between psychotic symptoms 
starting and an adolescent seeking treatment. A frequent barrier to seeking 
assistance is the stigma associated with psychosis specifically and mental 
disorders more generally. As well, many of the actual symptoms of psychosis, 
such as suspiciousness, can militate against seeking help. Help seeking is 
often finally precipitated by a crisis, such as suicidal or violent behaviour.8
Once a young person is referred for assessment, the practitioner first 
needs to determine whether symptoms are due to psychosis or another 
condition, such as a delirium. If symptoms are caused by a psychosis, the 
practitioner then needs to establish which disorder is causal. For example, 
a practitioner may have to sort out whether an adolescent’s symptoms are 
due to schizophrenia or drug use. This process can be arduous; some studies 
have found that as many as 55% of individuals first presenting with psychotic 
symptoms receive different diagnoses within two to six years of their initial 
evaluation.18 Nonetheless, providing an accurate diagnosis is critical. If a 
psychosis is due to an underlying medical condition, it will often resolve once 
the underlying condition is treated. If the psychosis is due to schizophrenia, 
appropriate early treatment can improve outcomes.
Given these challenges, when a youth is suspected of having a psychosis, 
a careful evaluation by an experienced practitioner is essential. A qualified 
child and adolescent psychiatrist working with an interdisciplinary mental 
health team can provide the type of comprehensive assessment needed.
Overview continued
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The evaluation process requires considerable time and effort. Clinical 
interviews with youth and family members are essential. To help in this 
process, there are many structured interviews designed for gathering 
information about psychotic symptoms in children and adolescents. 
Practitioners should be sensitive to the possibility of adolescents and their 
families underreporting the duration and severity of symptoms due to 
stigma, stress and fear.17 A medical evaluation and a review of developmental, 
medical and school records are also needed. Currently, no definitive blood or 
brain imaging tests have been established as a reliable diagnostic tool. When 
such tests are performed, they are usually done to rule out other treatable 
conditions, such as infections.
Additional challenges that accompany psychosis
Adolescents with psychotic disorders often have additional mental health 
concerns or concurrent problems. Those with schizophrenia frequently 
experience conduct disorder and depression.11 As well, rates of suicidal 
behaviour have been found to range from 11% to 26% during first episodes 
of psychosis.3 Suicide attempts are especially prevalent among youth using 
street drugs.3 Problems with cognition,19 language,2 motor skills and social 
issues10 also commonly co-occur with schizophrenia.
When schizophrenia begins in adolescence rather than adulthood, 
it can be associated with greater functional impairment, including 
less independence, poorer educational achievement and increased 
unemployment.19 However, given that a shorter time period between the 
onset of symptoms and receiving treatment is associated with a more positive 
outcome, there is much potential to help youth with psychosis.17
The financial costs
As well as causing personal burdens, schizophrenia is associated with 
significant financial costs. For example, adolescents and their families 
frequently incur medication expenses. In 2007, Canadians spent $629 million 
on antipsychotic drugs.20
Schizophrenia has also been identified as one of the world’s top 10 causes 
of disability-adjusted life-years.13 Adding to this, lifetime disability costs are 
far greater when schizophrenia begins in adolescence rather than adulthood. 
In Canada, the direct health care and non–health care costs of schizophrenia 
have been estimated at $2 billion annually (in 2004 CDN$).21 When lost 
productivity costs are included, the total cost reached nearly $7 billion in 
2004.
Overview continued
 We have enough 
evidence to know 
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What we can do to assist
There are effective treatments for youth with psychosis. Medications can 
lessen psychotic symptoms and improve general functioning. (Our Review 
article presents information on the efficacy and side effects of medications 
commonly used to treat adolescent psychosis.) However, adherence to 
medication regimens can be poor due to unpleasant side effects, denial of 
the disorder17 and a desire to not be different from peers.8 Practitioners can 
help to minimize medication side effects by using the lowest possible doses 
to control symptoms and by using adjunctive medications to address side 
effects. Regular monitoring is also essential.
In comprehensive treatment 
plans, psychosocial interventions 
are also frequently included. 
All young people and their 
families should be provided 
with educational information 
about these additional treatment 
options.10 As well, youth with 
schizophrenia typically require 
intensive community supports 
such as day programming, 
specialized education programs 
and vocational training.10
Regarding psychosocial 
therapies per se, preliminary 
evaluations offer encouraging 
results. Family therapy has been 
shown to be effective among 
adults (using randomized 
controlled trials) and among youth (using less rigorous evaluations).9 
However, there is still an absence of high-quality research on the effectiveness 
of cognitive-behavioural therapy (CBT) for teens experiencing psychosis. 
Given CBT’s demonstrated effectiveness with adults,9 evaluations with 
adolescents are warranted and needed. Despite these limitations, we have 
enough evidence to know that we can help youth with psychotic disorders.
What we tried to bring you — but could not
Many practitioners consider psychosocial interventions to be a vital component in 
treating psychosis. For example, a well-respected practice parameter stresses using 
a “comprehensive multimodal approach” to most effectively reduce symptoms 
and relapse rates among adolescents with schizophrenia.10 However, such 
recommendations come without high-quality evaluations supporting the use of 
psychosocial interventions. Our five-year search of four databases uncovered only 
one psychosocial treatment for adolescent psychosis evaluated using randomized 
controlled trials (RCTs) (see our Feature article).  We focus on RCTs because this 
research design helps to ensure that any improvements are due to the actual 
treatment rather than other factors. (See the In Commentary section of our first 
issue for further information about our research methodology.) In an effort to 
provide information on a broader array of psychosocial treatments, we searched 
two systematic reviews — including one that was not restricted to newer journal 
publications.9, 13 Despite our efforts, we did not locate any additional RCTs on 
psychosocial treatments for adolescents with psychosis. Rigorous evaluations of 
these treatments are greatly needed. Investing in such research will help to ensure 
that vulnerable youth are offered the best possible treatment choices.
Overview continued
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Antipsychotics:  
Prescribing for success
Medications are widely accepted as an essential treatment for psychosis in young people despite somewhat limited research on their effectiveness. 
Two recent systematic reviews22, 23 and one recent practice 
parameter10 uncovered only two English-language, 
randomized placebo-controlled trials of antipsychotics 
with individuals age 18 and younger. Both of the older 
antipsychotics evaluated — haloperidol and loxapine —  
were effective for young people with schizophrenia.24, 25
Since these evaluations occurred, many new 
antipsychotics have been developed, including risperidone 
and olanzapine. Most practitioners prescribe these newer 
medications when treating youth with psychosis.26 Because 
of this, there is a critical need for information on the effectiveness and side 
effects of these commonly prescribed antipsychotics. Consequently, we 
sought to identify and summarize the newest high-quality research available 
on the benefits and risks of medications used to treat psychosis in young 
people.
Our systematic method for selecting research
We used systematic methods adapted from the Cochrane Collaboration.27 We 
limited our search to randomized controlled trials (RCTs) published in peer-
reviewed scientific journals.
To identify studies, we first applied the following search strategy:
As well, we hand-searched previously published systematic reviews and all 
accepted RCTs for additional relevant publications.
Review
Sources • Medline, PsycINFO, CINAHL and CENTRAL
Search Terms • Schizophrenia, disorders with psychotic features or psychosis and prevention, treatment  
  or intervention
Limits • English-language articles published in 2004 through January 2009* 
 • Child participants aged 0–18 years 
*  We limited our search to five years given that our previous report Early Psychosis: A Review of the Treatment Literature9 included publications prior to 2004.
  With careful management, 
medications can dramatically improve 
functioning and reduce suffering for youth 
with psychosis.
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Next, we applied the following criteria to ensure we included only the 
highest-quality pertinent studies:
• Mean age of sample 18 years or less 
• Interventions aimed at preventing or treating psychosis 
• Clear descriptions of participant characteristics, settings and interventions
• Random assignment of participants to intervention and control/
comparison groups at study outset 
• Double blinding (for medication trials only) 
• Attrition rates below 20% or use of intention-to-treat analysis 
• Levels of statistical significance reported for all psychosis outcomes  
at final measurement period
Two different team members assessed each retrieved study to ensure accuracy.
Finding the highest-quality evaluations
Of the 11 evaluations retrieved for assessment, seven medication trials met 
our criteria. (The two psychosocial intervention trials that met our criteria 
are highlighted in our Feature article.) Table 2 presents the details of these 
studies. The medications evaluated included aripiprazole, clozapine (brand 
name Clozaril), haloperidol (formerly sold in Canada under the brand name 
Haldol), molindone, olanzapine (brand name Zyprexa) and risperidone 
(brand name Risperdal). 
All but two of the medications reviewed are for sale in Canada. 
Aripiprazole is classified as an investigational drug and is only available 
through Health Canada’s Special Access Programme (SAP). (The SAP considers 
practitioners’ requests for aripiprazole only after other treatments have 
been considered and ruled out — for reasons such an ineffectiveness and 
unsuitability). Molindone is not available in Canada. 
Three evaluations were placebo controlled28–30 while four directly 
compared two or more medications without a placebo.18, 26, 31, 32 One study 
was a prevention trial that included young people who had never had a 
psychotic disorder but were at high risk for psychosis.28 Among the six 
treatment studies, two were limited to youth with schizophrenia29, 30 and 
two were limited to young people with treatment-resistant schizophrenia32 
and/or treatment-resistant schizoaffective disorder.31 (Treatment resistant was 
defined as previous failures to respond to two antipsychotic medications.) 
The remaining two studies included young people with a range of psychotic 
disorders including schizophreniform disorder,18, 26 delusion disorder, and 
Review continued
 Among medications 
for sale in Canada, 
clozapine, haloperidol, 
olanzapine and 
risperidone have solid 
evidence supporting 
their effectiveness in 
treating psychosis in 
young people.  
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depression and bipolar disorder with psychotic features.18 Although most 
studies included only American participants,18, 26, 31, 32 children and youth from 
Canada,33 Russia,30 Africa, South America, Asia, Europe and the Caribbean29 
participated in three studies.
Funding research: Who’s paying the bills?
In five of the studies, at least one author received research funding from a 
drug company.18, 26, 28–30 Only one study was conducted by researchers with no 
financial relationship to pharmaceutical firms.31 The authors in the remaining 
study did not disclose whether there was drug company funding.32
Medication Mean Daily Dose Number of Medication Participant Age Participant 
(brand name)* (milligrams)** Participants  Duration† (years)  Gender 
 Placebo-controlled trials — Prevention
 Olanzapine28 5–15‡ Medication: 31 52 weeks Mean: 18 65% male 
 (Zyprexa)  Placebo: 29   Range: 12–36  
 Placebo-controlled trials — Treatment
 Aripiprazole29 10 or 29 Medication: 202 6 weeks Mean: 16 57% male 
    Placebo: 100  Range: 13–17
 Olanzapine30 11  Medication: 72 6 weeks Mean: 16 70% male 
   Placebo: 35   Range: 13–17
 Medication comparison trials — Treatment
 Clozapine31 403  18 12 weeks Mean: 16 54% male 
 (Clozaril)    Range: 10–18 
 Olanzapine  26  21  
 Clozapine32 327  12 8 weeks Mean: 12 60% male 
 Olanzapine 18  13  Range: 7–16
 Haloperidol18 5  15 8 weeks Mean: 15 60% male 
 Olanzapine 12  16  Range: 8–19 
 Risperidone  4  20 
 (Risperdal)   
 Molindone26   60  41 8 weeks Mean: NR 65% male 
 Olanzapine  11  36  Range: 8–19 
 Risperidone 3  42  
NR Not reported
* Where applicable, brand names are provided for drugs currently sold in Canada.
** Different medications have different standard dosages. Therefore, a medication with a higher mean daily dose than another medication cannot be  
assumed to be a stronger dose. 
† During RCT phase of study.  
‡ Authors only reported medication dose range. 
Table 2:  Medications assessed
Review continued
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We can treat psychosis but can we prevent it?
In the placebo-controlled evaluations, olanzapine was not effective in 
preventing the onset of psychosis among children and youth at high risk for 
developing the condition.28 Olanzapine was, however, effective in reducing 
positive symptoms, general symptoms and psychosis severity among 
schizophrenic youth.30 Similarly, aripiprazole was effective in reducing 
positive symptoms, negative symptoms and psychosis severity and in 
improving remission rates, global functioning and quality of life among youth 
with schizophrenia.29
In evaluations directly comparing medications, clozapine was superior to 
olanzapine among treatment-resistant children and youth with schizophrenia 
for both overall response rate and negative symptoms in one trial31 and for 
negative symptoms and rapidity of symptom improvement in another trial.32
In separate trials comparing olanzapine and risperidone to haloperidol18 
and to molindone26 among children and youth with a variety of psychotic 
disorders, no significant differences were found between the medications on 
any symptom outcome measure. In one trial, however, children and youth 
treated with olanzapine had a significantly shorter medication response 
time (1.6 weeks) than children and youth treated with either risperidone 
(2.3 weeks) or haloperidol (2.4 weeks).18 All four medications produced 
significant reductions in psychotic symptoms from baseline to treatment 
end, with effect sizes ranging from 0.5 to 1.818 and average symptom declines 
ranging from 21% to 47%.26 Table 3 presents findings from all the medication 
comparison trials.
Table 3:  Medication outcomes from comparison evaluations 
Clozapine31 significantly better than Olanzapine on:  
• response rate* (66% versus 33%) • negative symptoms
Clozapine32 significantly better than Olanzapine on:   
• rapidity of symptom improvement • negative symptoms
Olanzapine18 significantly better than Haloperidol and Risperidone on: 
• rapidity of symptom improvement 
Olanzapine, Risperidone and Molidone26 were not significantly different on any outcome measure 
* Response rate defined as ≥ 30% decrease in symptoms and psychosis improvement rated as much/very much improved.
Review continued
Recognizing the limitations
Despite restricting our review to the highest-quality studies, the evaluations 
still had limitations. Most studies had very small sample sizes, which 
limited the likelihood of identifying small to moderate effects. As a result, 
some clinically significant benefits of the medications may have been 
underestimated. As well, four of the medications — clozapine, haloperidol, 
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risperidone and molindone — were evaluated without a placebo control. As 
a result, improvements due to factors other than the medications themselves 
cannot be ruled out.34 However, the fact that each medication was compared 
to olanzapine, which was proven effective in placebo-controlled RCTs, 
increases confidence in the positive findings.
Risks that accompany benefits
Side effects and adverse events were reported for all the medications evaluated, 
despite their use being limited to 12 weeks or less in most studies. Side 
effects generally constituted symptoms that were serious but manageable. 
In contrast, adverse events generally constituted symptoms that posed 
significant threats to the young person’s health and often necessitated 
stopping the medication.
Regarding side effects, all medications produced neurological (or 
extrapyramidal) symptoms, including involuntary movements and 
restlessness. In one study, the majority of participants required adjunctive 
medications (low-dose anticholinergics) to control these symptoms (67% 
on haloperidol, 56% on olanzapine and 53% on risperidone).18 Weight gain 
was another common side effect for all the medications except molindone. 
Average gains ranged from 3.5 kilograms (for haloperidol) to 7.1 kilograms 
(for olanzapine) after only eight weeks of medication use.26
Many additional side effects were reported. Among medications for 
general sale in Canada — clozapine, haloperidol, olanzapine and risperidone 
— all produced sweats/chills, constipation and dry mouth. Olanzapine 
was further associated with elevated blood sugar levels, which puts young 
people at risk of future diabetes.31 Clozapine was associated with increased 
blood lipid levels, which puts young people at risk of future cardiovascular 
disease.31, 32 As well, clozapine produced increased salivation.31
Regarding adverse events, olanzapine was associated with abnormalities in 
both liver and heart functioning30, 32 as well as significantly reduced counts of 
neutrophils (one of the white blood cells essential for fighting infections).31, 32  
Similarly, clozapine was linked to abnormalities in heart functioning32 
and significantly reduced neutrophil counts,32 seizures32 and upper bowel 
obstruction.31 Although not found in the current studies, agranulocytosis, a 
potentially fatal condition, can be associated with clozapine use. In this rare 
condition, white blood cell counts drop dramatically, leaving individuals 
extremely vulnerable to infections.10 The potential for agranulocytosis 
necessitates regular blood tests and close monitoring for anyone using this 
medication.
Review continued
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Practice applications
Among medications for general sale in Canada, clozapine, haloperidol, 
olanzapine and risperidone have solid evidence supporting their effectiveness 
in treating psychosis in young people. Deciding which medication to 
prescribe requires practitioners to carefully consider many factors, including 
effectiveness, side effect profile and cost. For example, clozapine — although 
highly effective — is typically reserved for youth who have not responded to 
at least two other antipsychotic medications because of its side effect profile.10 
When price is a consideration, older antipsychotics have the benefit of 
costing less35 while having similar effectiveness profiles.18, 26
Once an appropriate antipsychotic is prescribed, practitioners can take 
steps to maximize benefits and minimize risks. As with any treatment, 
evaluation of effectiveness and side effects should be ongoing. Youth should 
initially be monitored at least 
weekly.10 Such monitoring often 
includes physical examinations 
such as measuring weight 
and assessing for neurological 
problems. As well, regular 
laboratory tests such as heart and 
liver functioning along with white 
blood cell counts can help monitor 
and manage side effects.10 
With careful management, 
medications can dramatically 
improve functioning and reduce 
suffering for youth with psychosis. 
For the best possible long-term 
outcomes, medications are best 
prescribed by practitioners working 
in collaboration with youth and 
their families as partners in the 
process.
Review continued
Use of antipsychotics surges dramatically
On July 2, many people were shocked to hear a Canadian Broadcasting Corporation 
news anchor announce a striking increase in antipsychotic prescriptions to B.C. 
children. The CBC reported on data released by the Therapeutics Initiative (TI), 
which conducts independent medication reviews. The TI’s examination of health 
databases (PharmaNet and the Medical Services Plan) revealed a tenfold increase 
over the past decade in prescriptions for risperidone, quetiapine, olanzapine and 
clozapine among children ages 14 and younger.51 This dramatic rise is particularly 
alarming given the age of the children and the very limited research on the 
effectiveness and safety of these medications. To ensure that only children who 
require such medications receive them, prescriptions should be considered only 
after a comprehensive evaluation by a qualified practitioner. 
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Figure 1: Trends in antipsychotic use among B.C. children  
 age 14 and younger
One-year period prevalence refers to the percentage of children in BC who were dispensed risperidone, 
quetiapine, olanzapine and clozapine. Source: Therapeutics Initiative (2009).
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Feature
Skills beyond pills:  
Boosting brain power
Youth with psychosis typically experience cognitive difficulties, including impairments in attention, memory, planning and flexible 
thinking.6 Cognitive Remediation Therapy (CRT), which 
teaches information processing strategies through 
guided mental exercises,19 was specifically developed 
to address these types of difficulties. Here we present 
two randomized controlled trials of CRT, the only 
psychosocial treatment that met the rigorous acceptance 
criteria described in our Review article.
Both evaluations took place in Europe. The 
Norwegian study included adolescents with a variety 
of psychotic disorders (for which 77% were being 
treated with antipsychotic medications).36 All youth 
— regardless of treatment assignment — participated in 
a psycho-educational program, which included parent 
seminars, problem-solving sessions and milieu therapy. 
In contrast, the UK study was limited to youth with 
schizophrenia on a stable medication for at least one 
month.19 Participants also had to have difficulties with 
cognitive and social functioning. Interventions and 
participant characteristics are described in Table 4.
Table 4:  Cognitive Remediation Therapy (CRT) — Program and study descriptions
Location Participant  Intervention Description and Length Participant Age Participant   
 Number  (years) Gender 
Norway36, 37 CRT = 14  Mean: 15 54% male 
 Control = 12  Range: 12–18
United Kingdom19 CRT = 21  Mean: 18 65% male 
 Standard care = 19  Range: 14–22
Problem-solving, attention, memory and social 
perception skills taught by schoolteachers and 
therapist for 30 hours (plus 15-minute work sessions) 
over 12 weeks
Memory, planning and problem-solving tasks 
demonstrated by therapist and then practised 
overtly and covertly by youth for 40 hours over  
12 weeks
  Youth receiving CRT showed significantly better visual 
information processing skills.
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Brain training:  
Is it worth the effort?
The Norwegian study found only one significant 
difference between CRT and control group 
participants at 12-month follow-up (for details, see 
Table 5). Youth receiving CRT showed significantly 
better visual information processing skills when 
intellectual functioning was controlled for. 
Interestingly, this improvement was not present at 
three-month follow-up.
The UK evaluation also found only one 
significant improvement. At three-month follow-
up, youth who received CRT improved more on 
a test of cognitive flexibility (effect size 0.6) than 
youth who received standard care. Although there 
were no significant differences between treatments 
on any non-cognitive outcome measures, CRT was 
found to have a moderating effect on psychiatric 
outcomes. Improvements in cognitive planning 
were associated with decreases in psychiatric 
symptoms only among youth who received CRT.
Teaching cognitive skills — What’s involved 
Ueland and Rund37 provided the following description of the goals 
and training components included in their CRT program:   
Module Goals Tasks 
Card sorting  
Matching synonyms and antonyms  
Word association 
 
Identifying items in cartoon drawings 
Identifying target letters within array  
Mazes 
 
Object memorization 
Sentence repetition 
Describing, interpreting and 
discussing the social meaning of 
slides portraying actors in social 
activities
Cognitive Differentiation: 
Improving cognitive skills to 
enhance social interactions 
and problem-solving abilities
Attention: Bettering selective 
attention, sustained attention 
and visual scanning abilities
Memory: Strengthening 
verbal and visual memory
Social Perception: Improving 
social knowledge by 
enhancing attention to 
relevant social information
Feature continued
  Youth who received CRT improved 
more on a test of cognitive flexibility than 
youth who received standard care.
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Detecting the differences: The power in numbers
These two recent evaluations provide evidence that CRT can address two 
common problems experienced by youth with psychosis — improving both 
cognitive flexibility and visual information processing. Given that these gains 
were found between three and twelve months after the training programs 
ended, there is good evidence that CRT can produce long-lasting benefits. 
CRT also may produce improvements not identified in these evaluations. 
Because both studies had very small sample sizes, the power to detect benefits 
from CRT was very limited. This means that even greater gains might have 
been found if the studies had more participants. Accordingly, although only 
two improvements were found, larger evaluations of CRT are well warranted. 
It would be particularly helpful to assess the impact of CRT on functioning in 
daily living to ensure that any benefits produced are clinically meaningful as 
well as statistically significant.
Table 5:  Evaluations of Cognitive Remediation Therapy (CRT)
Evaluation Period Outcomes Favouring CRT Non-significant Outcomes
3-month follow-up19  Cognitive flexibility  Cognitive Functional 
   Memory  Psychiatric symptoms 
   Planning  Self-esteem 
    Social functioning and relationship quality
12-month follow-up37  Visual information processing  Cognitive Functional 
   Attention  Global functioning 
   Cognitive flexibility  Psychiatric symptoms 
   Executive functioning  
   Verbal and visual memory
Feature continued
 There is good 
evidence that CRT can 
produce long-lasting 
benefits.
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Letters
Adhering to the manual:  
How much does it matter? 
To the Editors:
Your recent article on Multisystemic Therapy (MST) highlighted 
both the very successful outcomes achieved by this treatment in the 
United States and the less promising findings among youth from other 
countries, including Canada. It is important to recognize that in some 
trials where MST has failed to reduce behavioural problems, concerns 
with poor treatment fidelity have been raised. Such results suggest that 
how well the treatment has been implemented can have as dramatic 
effects on outcomes as where it is implemented.
Bob Pushak
Port Moody, BC
Treatment fidelity, defined as the degree to which the intervention was 
delivered as intended, is recognized as a variable that can influence clinical 
outcomes. Nonetheless, it is infrequently assessed in therapeutic outcome 
research. A recent review of 342 studies found only 27% evaluated whether 
the intervention was delivered as specified.38 When treatment fidelity is 
not monitored, alternative explanations for the success or failure of the 
intervention cannot be ruled out. For example, an intervention  
with significant benefits could be due to a practitioner adding a novel 
treatment component. Alternatively, a lack of success could be due to 
omission of a key element of the intervention.
Consistently assessing treatment fidelity
A strength of many MST evaluations is the use of a treatment fidelity 
measure, namely the Therapist Adherence Measure-Revised (TAM-R).39 
This 26-item scale can be completed by therapists, parents and/or youth to 
assess therapists’ adherence to MST principles during treatment sessions.40 
Although studies measuring the relationship between MST treatment fidelity 
and clinical outcomes have been inconsistent, many have found a positive 
association, as shown in Table 6.
In contrast, some studies have found no relationship between treatment 
fidelity and clinical outcomes. For example, treatment fidelity scores 
were unrelated to any recidivism outcome measure in a Canadian MST 
evaluation.46 As well, improvements have still been reported for youth 
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receiving MST delivered with poor treatment fidelity, including reductions in 
externalizing behaviours and criminal activity among American youth.47 Even 
among studies finding an overall positive relationship between fidelity and 
clinical gains, some unexpected process level outcomes have been found.40 
For example, in a study of American adolescents, youth-rated family-
therapist conflict (reflecting poor adherence to the MST treatment model) 
was associated with less delinquent peer affiliation while caregiver-rated 
therapist-directed sessions (reflecting high MST adherence) was associated 
with more delinquent behaviour.48
Concerns have also been raised regarding MST’s treatment fidelity 
measure. The MST Cochrane review authors noted that the TAM-R assesses 
constructs that are not unique to MST, such as engagement, treatment 
participation and therapeutic alliance.49 As well, correlations between  
TAM-R ratings from youth, parents and therapists have been quite low in 
some studies.40
Applauding the effort
Despite the acknowledged concerns, attempts by researchers to understand 
the relationship between MST treatment fidelity and outcomes should be 
recognized and encouraged. Researchers also need to continue to explore 
additional explanations when programs produce inconsistent outcomes. 
Other important variables that need ongoing evaluation include participant 
characteristics, comparison services offered, and differing law and policies 
across regions and nations.50 With efforts to better understand factors 
influencing treatment outcomes, we can help to consistently deliver effective 
interventions to children and families.
Table 6:  MST studies with positive relationships between treatment fidelity and outcomes 
Country  Outcome
 Norway Treatment sites with the lowest fidelity scores had the least favourable outcomes while those with the highest scores 
had the best outcomes.* 41
 Sweden Although MST was not more successful than usual treatment services, high treatment fidelity was associated with 
fewer arrests and better social competence. 42
 United States Improvement in official rearrest rates achieved among youth who received MST delivered with high fidelity.** 43
 United States Substantially better outcomes associated with high treatment adherence ratings among youth engaged in criminal 
activity with and without co-occurring substance abuse. 40
 United States High parent and adolescent treatment adherence ratings predicted low rearrest rates. High therapist treatment 
adherence ratings predicted low criminal offence and incarceration rates. 44
 Multiple nations Among 16,764 youth, average therapist adherence at international sites was significantly lower than at American 
sites. International sites had poorer results on arrest rates and youth engagement in school or work.* 45
* Study authors did not report whether tests of statistical significance between fidelity and outcome measures were performed.
** A statistical examination of the relationship was not conducted because of the limited availability of treatment fidelity data.
Letters continued
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BC government staff can access original articles from BC’s Health and Human 
Services Library. 
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